Moreover, in both solid and hematological tumors, Cu-DSF has been shown to preferentially target cancer cells and can also selectively target and kill ALDH+ MM stem cell populations that lead to chemoradiotherapy resistance and recurrence (Yip et al., 2011; Liu et al., 2013; Xu et al., 2017; Jin et al., 2018; Wu et al., 2019; Sun et al., 2020). This evidence concerns the gene LDHA and Miyoshi myopathy.